Embryonal rhabdomyosarcoma (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Embryonal rhabdomyosarcoma" in English language version.

refsWebsite

Global rank English rank

55nih.gov

4^th place

33doi.org

2^nd place

8semanticscholar.org

11^th place

8^th place

2cancer.gov

1,684^th place

1,350^th place

1cancer.org

3,680^th place

2,918^th place

1cancer.net

low place

cancer.gov

"Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version - NCI". www.cancer.gov. 2022. Retrieved 2022-07-25.
"Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version - NCI". www.cancer.gov. 2022-05-23. Retrieved 2022-08-01.

cancer.net

"Rhabdomyosarcoma - Childhood - Types of Treatment". Cancer.Net. 2012-06-25. Retrieved 2022-08-01.

cancer.org

"What Is Rhabdomyosarcoma?". www.cancer.org. Retrieved 2022-07-28.

doi.org

Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M (2009). "Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion". BMC Cancer. 9: 304. doi:10.1186/1471-2407-9-304. PMC 2743710. PMID 19715595.
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. (2014). "Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors". Cancer Discovery. 4 (2): 216–231. doi:10.1158/2159-8290.CD-13-0639. PMC 4462130. PMID 24436047.
Yohe ME, Heske CM, Stewart E, Adamson PC, Ahmed N, Antonescu CR, et al. (2019). "Insights into pediatric rhabdomyosarcoma research: Challenges and goals". Pediatric Blood & Cancer. 66 (10): e27869. doi:10.1002/pbc.27869. PMC 6707829. PMID 31222885.
Kikuchi K, Rubin BP, Keller C (2011). "Developmental origins of fusion-negative rhabdomyosarcomas". Current Topics in Developmental Biology. 96: 33–56. doi:10.1016/B978-0-12-385940-2.00002-4. ISBN 9780123859402. PMC 6250435. PMID 21621066.
Rodeberg D, Paidas C (2006). "Childhood rhabdomyosarcoma". Seminars in Pediatric Surgery. Childhood Cancer. 15 (1): 57–62. doi:10.1053/j.sempedsurg.2005.11.009. PMID 16458847. S2CID 1220308.
Ibrahim U, Saqib A, Mohammad F, Ding J, Salman B, Collado FK, Dhar M (2017). "Embryonal Rhabdomyosarcoma of the Cervix: A Rare Disease at an Uncommon Age". Cureus. 9 (11): e1864. doi:10.7759/cureus.1864. PMC 5773277. PMID 29375950.
Ricker CA, Crawford K, Matlock K, Lathara M, Seguin B, Rudzinski ER, et al. (2020). "Defining an embryonal rhabdomyosarcoma endotype". Cold Spring Harbor Molecular Case Studies. 6 (2): a005066. doi:10.1101/mcs.a005066. PMC 7133750. PMID 32238403.
Fan R, Parham DM, Wang LL (2022). "An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma". Archives of Pathology & Laboratory Medicine. 146 (8): 953–959. doi:10.5858/arpa.2021-0183-RA. PMID 35051261. S2CID 246078793.
Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. (2013). "Targeting oxidative stress in embryonal rhabdomyosarcoma". Cancer Cell. 24 (6): 710–724. doi:10.1016/j.ccr.2013.11.002. PMC 3904731. PMID 24332040.
Arnold MA, Barr FG (2017). "Molecular diagnostics in the management of rhabdomyosarcoma". Expert Review of Molecular Diagnostics. 17 (2): 189–194. doi:10.1080/14737159.2017.1275965. PMC 5657295. PMID 28058850.
Dziuba I, Kurzawa P, Dopierała M, Larque AB, Januszkiewicz-Lewandowska D (2018). "Rhabdomyosarcoma in children - current pathologic and molecular classification". Polish Journal of Pathology. 69 (1): 20–32. doi:10.5114/pjp.2018.75333. PMID 29895123.
Karakas Z, Agaoglu L, Biner B, Devecioglu O, Anak S, Yalman N, et al. (August 2000). "Results of rhabdomyosarcoma treatment in a developing country". Acta Medica Okayama. 54 (4): 173–177. doi:10.18926/AMO/32277. PMID 10985177.
Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (September 2009). "Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005". Cancer. 115 (18): 4218–4226. doi:10.1002/cncr.24465. PMC 2953716. PMID 19536876.
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. (January 2019). "Rhabdomyosarcoma". Nature Reviews. Disease Primers. 5 (1): 1. doi:10.1038/s41572-018-0051-2. PMC 7456566. PMID 30617281.
Leiner J, Le Loarer F (2020). "The current landscape of rhabdomyosarcomas: an update". Virchows Archiv. 476 (1): 97–108. doi:10.1007/s00428-019-02676-9. PMID 31696361. S2CID 207911529.
Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, et al. (2021). "Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium". Journal of Clinical Oncology. 39 (26): 2859–2871. doi:10.1200/JCO.20.03060. PMC 8425837. PMID 34166060.
Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, et al. (2018). "MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma". Science Translational Medicine. 10 (448): eaan4470. doi:10.1126/scitranslmed.aan4470. PMC 8054766. PMID 29973406.
Agaram NP (2022). "Evolving classification of rhabdomyosarcoma". Histopathology. 80 (1): 98–108. doi:10.1111/his.14449. PMC 9425116. PMID 34958505. S2CID 245501811.
Parham DM, Barr FG (2013). "Classification of rhabdomyosarcoma and its molecular basis". Advances in Anatomic Pathology. 20 (6): 387–397. doi:10.1097/PAP.0b013e3182a92d0d. PMC 6637949. PMID 24113309.
Frankart AJ, Breneman JC, Pater LE (2021). "Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma". Cancers. 13 (14): 3567. doi:10.3390/cancers13143567. PMC 8305800. PMID 34298780.
Jawad N, McHugh K (2019). "The clinical and radiologic features of paediatric rhabdomyosarcoma". Pediatric Radiology. 49 (11): 1516–1523. doi:10.1007/s00247-019-04386-5. PMID 31620851. S2CID 204709484.
Breitfeld PP, Meyer WH (2005). "Rhabdomyosarcoma: new windows of opportunity". The Oncologist. 10 (7): 518–527. doi:10.1634/theoncologist.10-7-518. PMID 16079319. S2CID 24136175.
Wang X, Feng J, Li Z, Zhang X, Chen J, Feng G (2020). "Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database". Pediatric Investigation. 4 (4): 242–249. doi:10.1002/ped4.12220. PMC 7768301. PMID 33376951.
Frankart AJ, Breneman JC, Pater LE (2021). "Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma". Cancers. 13 (14): 3567. doi:10.3390/cancers13143567. PMC 8305800. PMID 34298780.
Yu PY, Guttridge DC (2018). "Dysregulated Myogenesis in Rhabdomyosarcoma". Current Topics in Developmental Biology. 126: 285–297. doi:10.1016/bs.ctdb.2017.10.007. ISBN 9780128092156. PMID 29305002.
Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, et al. (2014). "A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations". Nature Genetics. 46 (6): 595–600. doi:10.1038/ng.2969. PMC 4231202. PMID 24793135.
Rudzinski ER, Anderson JR, Hawkins DS, Skapek SX, Parham DM, Teot LA (2015). "The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group". Archives of Pathology & Laboratory Medicine. 139 (10): 1281–1287. doi:10.5858/arpa.2014-0475-OA. PMC 4651658. PMID 25989287.
Dasgupta R, Rodeberg DA (February 2012). "Update on rhabdomyosarcoma". Seminars in Pediatric Surgery. Childhood Solid Tumors. 21 (1): 68–78. doi:10.1053/j.sempedsurg.2011.10.007. PMID 22248972.
Darwish C, Shim T, Sparks AD, Chillakuru Y, Strum D, Benito DA, Monfared A (December 2020). "Pediatric head and neck rhabdomyosarcoma: An analysis of treatment and survival in the United States (1975-2016)". International Journal of Pediatric Otorhinolaryngology. 139: 110403. doi:10.1016/j.ijporl.2020.110403. PMID 33049553. S2CID 222351840.
Chen C, Dorado Garcia H, Scheer M, Henssen AG (2019). "Current and Future Treatment Strategies for Rhabdomyosarcoma". Frontiers in Oncology. 9: 1458. doi:10.3389/fonc.2019.01458. PMC 6933601. PMID 31921698.
Hiniker SM, Donaldson SS (2015-05-12). "Recent advances in understanding and managing rhabdomyosarcoma". F1000Prime Reports. 7: 59. doi:10.12703/P7-59. PMC 4447051. PMID 26097732.
Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H (July 2020). "Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma". Cancers. 12 (7): 1758. doi:10.3390/cancers12071758. PMC 7409313. PMID 32630642.
van Erp AE, Versleijen-Jonkers YM, van der Graaf WT, Fleuren ED (July 2018). "Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma". Molecular Cancer Therapeutics. 17 (7): 1365–1380. doi:10.1158/1535-7163.MCT-17-1131. PMID 29967215. S2CID 49648448.

nih.gov

pubmed.ncbi.nlm.nih.gov

Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M (2009). "Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion". BMC Cancer. 9: 304. doi:10.1186/1471-2407-9-304. PMC 2743710. PMID 19715595.
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. (2014). "Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors". Cancer Discovery. 4 (2): 216–231. doi:10.1158/2159-8290.CD-13-0639. PMC 4462130. PMID 24436047.
Yohe ME, Heske CM, Stewart E, Adamson PC, Ahmed N, Antonescu CR, et al. (2019). "Insights into pediatric rhabdomyosarcoma research: Challenges and goals". Pediatric Blood & Cancer. 66 (10): e27869. doi:10.1002/pbc.27869. PMC 6707829. PMID 31222885.
Kikuchi K, Rubin BP, Keller C (2011). "Developmental origins of fusion-negative rhabdomyosarcomas". Current Topics in Developmental Biology. 96: 33–56. doi:10.1016/B978-0-12-385940-2.00002-4. ISBN 9780123859402. PMC 6250435. PMID 21621066.
Rodeberg D, Paidas C (2006). "Childhood rhabdomyosarcoma". Seminars in Pediatric Surgery. Childhood Cancer. 15 (1): 57–62. doi:10.1053/j.sempedsurg.2005.11.009. PMID 16458847. S2CID 1220308.
Ibrahim U, Saqib A, Mohammad F, Ding J, Salman B, Collado FK, Dhar M (2017). "Embryonal Rhabdomyosarcoma of the Cervix: A Rare Disease at an Uncommon Age". Cureus. 9 (11): e1864. doi:10.7759/cureus.1864. PMC 5773277. PMID 29375950.
Ricker CA, Crawford K, Matlock K, Lathara M, Seguin B, Rudzinski ER, et al. (2020). "Defining an embryonal rhabdomyosarcoma endotype". Cold Spring Harbor Molecular Case Studies. 6 (2): a005066. doi:10.1101/mcs.a005066. PMC 7133750. PMID 32238403.
Fan R, Parham DM, Wang LL (2022). "An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma". Archives of Pathology & Laboratory Medicine. 146 (8): 953–959. doi:10.5858/arpa.2021-0183-RA. PMID 35051261. S2CID 246078793.
Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. (2013). "Targeting oxidative stress in embryonal rhabdomyosarcoma". Cancer Cell. 24 (6): 710–724. doi:10.1016/j.ccr.2013.11.002. PMC 3904731. PMID 24332040.
Arnold MA, Barr FG (2017). "Molecular diagnostics in the management of rhabdomyosarcoma". Expert Review of Molecular Diagnostics. 17 (2): 189–194. doi:10.1080/14737159.2017.1275965. PMC 5657295. PMID 28058850.
Dziuba I, Kurzawa P, Dopierała M, Larque AB, Januszkiewicz-Lewandowska D (2018). "Rhabdomyosarcoma in children - current pathologic and molecular classification". Polish Journal of Pathology. 69 (1): 20–32. doi:10.5114/pjp.2018.75333. PMID 29895123.
Karakas Z, Agaoglu L, Biner B, Devecioglu O, Anak S, Yalman N, et al. (August 2000). "Results of rhabdomyosarcoma treatment in a developing country". Acta Medica Okayama. 54 (4): 173–177. doi:10.18926/AMO/32277. PMID 10985177.
Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (September 2009). "Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005". Cancer. 115 (18): 4218–4226. doi:10.1002/cncr.24465. PMC 2953716. PMID 19536876.
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. (January 2019). "Rhabdomyosarcoma". Nature Reviews. Disease Primers. 5 (1): 1. doi:10.1038/s41572-018-0051-2. PMC 7456566. PMID 30617281.
Leiner J, Le Loarer F (2020). "The current landscape of rhabdomyosarcomas: an update". Virchows Archiv. 476 (1): 97–108. doi:10.1007/s00428-019-02676-9. PMID 31696361. S2CID 207911529.
Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, et al. (2021). "Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium". Journal of Clinical Oncology. 39 (26): 2859–2871. doi:10.1200/JCO.20.03060. PMC 8425837. PMID 34166060.
Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, et al. (2018). "MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma". Science Translational Medicine. 10 (448): eaan4470. doi:10.1126/scitranslmed.aan4470. PMC 8054766. PMID 29973406.
Agaram NP (2022). "Evolving classification of rhabdomyosarcoma". Histopathology. 80 (1): 98–108. doi:10.1111/his.14449. PMC 9425116. PMID 34958505. S2CID 245501811.
Parham DM, Barr FG (2013). "Classification of rhabdomyosarcoma and its molecular basis". Advances in Anatomic Pathology. 20 (6): 387–397. doi:10.1097/PAP.0b013e3182a92d0d. PMC 6637949. PMID 24113309.
Frankart AJ, Breneman JC, Pater LE (2021). "Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma". Cancers. 13 (14): 3567. doi:10.3390/cancers13143567. PMC 8305800. PMID 34298780.
Jawad N, McHugh K (2019). "The clinical and radiologic features of paediatric rhabdomyosarcoma". Pediatric Radiology. 49 (11): 1516–1523. doi:10.1007/s00247-019-04386-5. PMID 31620851. S2CID 204709484.
Breitfeld PP, Meyer WH (2005). "Rhabdomyosarcoma: new windows of opportunity". The Oncologist. 10 (7): 518–527. doi:10.1634/theoncologist.10-7-518. PMID 16079319. S2CID 24136175.
Wang X, Feng J, Li Z, Zhang X, Chen J, Feng G (2020). "Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database". Pediatric Investigation. 4 (4): 242–249. doi:10.1002/ped4.12220. PMC 7768301. PMID 33376951.
Frankart AJ, Breneman JC, Pater LE (2021). "Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma". Cancers. 13 (14): 3567. doi:10.3390/cancers13143567. PMC 8305800. PMID 34298780.
Yu PY, Guttridge DC (2018). "Dysregulated Myogenesis in Rhabdomyosarcoma". Current Topics in Developmental Biology. 126: 285–297. doi:10.1016/bs.ctdb.2017.10.007. ISBN 9780128092156. PMID 29305002.
Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, et al. (2014). "A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations". Nature Genetics. 46 (6): 595–600. doi:10.1038/ng.2969. PMC 4231202. PMID 24793135.
Rudzinski ER, Anderson JR, Hawkins DS, Skapek SX, Parham DM, Teot LA (2015). "The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group". Archives of Pathology & Laboratory Medicine. 139 (10): 1281–1287. doi:10.5858/arpa.2014-0475-OA. PMC 4651658. PMID 25989287.
Dasgupta R, Rodeberg DA (February 2012). "Update on rhabdomyosarcoma". Seminars in Pediatric Surgery. Childhood Solid Tumors. 21 (1): 68–78. doi:10.1053/j.sempedsurg.2011.10.007. PMID 22248972.
Darwish C, Shim T, Sparks AD, Chillakuru Y, Strum D, Benito DA, Monfared A (December 2020). "Pediatric head and neck rhabdomyosarcoma: An analysis of treatment and survival in the United States (1975-2016)". International Journal of Pediatric Otorhinolaryngology. 139: 110403. doi:10.1016/j.ijporl.2020.110403. PMID 33049553. S2CID 222351840.
Chen C, Dorado Garcia H, Scheer M, Henssen AG (2019). "Current and Future Treatment Strategies for Rhabdomyosarcoma". Frontiers in Oncology. 9: 1458. doi:10.3389/fonc.2019.01458. PMC 6933601. PMID 31921698.
Hiniker SM, Donaldson SS (2015-05-12). "Recent advances in understanding and managing rhabdomyosarcoma". F1000Prime Reports. 7: 59. doi:10.12703/P7-59. PMC 4447051. PMID 26097732.
Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H (July 2020). "Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma". Cancers. 12 (7): 1758. doi:10.3390/cancers12071758. PMC 7409313. PMID 32630642.
van Erp AE, Versleijen-Jonkers YM, van der Graaf WT, Fleuren ED (July 2018). "Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma". Molecular Cancer Therapeutics. 17 (7): 1365–1380. doi:10.1158/1535-7163.MCT-17-1131. PMID 29967215. S2CID 49648448.

ncbi.nlm.nih.gov

Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M (2009). "Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion". BMC Cancer. 9: 304. doi:10.1186/1471-2407-9-304. PMC 2743710. PMID 19715595.
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. (2014). "Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors". Cancer Discovery. 4 (2): 216–231. doi:10.1158/2159-8290.CD-13-0639. PMC 4462130. PMID 24436047.
Yohe ME, Heske CM, Stewart E, Adamson PC, Ahmed N, Antonescu CR, et al. (2019). "Insights into pediatric rhabdomyosarcoma research: Challenges and goals". Pediatric Blood & Cancer. 66 (10): e27869. doi:10.1002/pbc.27869. PMC 6707829. PMID 31222885.
Kikuchi K, Rubin BP, Keller C (2011). "Developmental origins of fusion-negative rhabdomyosarcomas". Current Topics in Developmental Biology. 96: 33–56. doi:10.1016/B978-0-12-385940-2.00002-4. ISBN 9780123859402. PMC 6250435. PMID 21621066.
Ibrahim U, Saqib A, Mohammad F, Ding J, Salman B, Collado FK, Dhar M (2017). "Embryonal Rhabdomyosarcoma of the Cervix: A Rare Disease at an Uncommon Age". Cureus. 9 (11): e1864. doi:10.7759/cureus.1864. PMC 5773277. PMID 29375950.
Ricker CA, Crawford K, Matlock K, Lathara M, Seguin B, Rudzinski ER, et al. (2020). "Defining an embryonal rhabdomyosarcoma endotype". Cold Spring Harbor Molecular Case Studies. 6 (2): a005066. doi:10.1101/mcs.a005066. PMC 7133750. PMID 32238403.
Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. (2013). "Targeting oxidative stress in embryonal rhabdomyosarcoma". Cancer Cell. 24 (6): 710–724. doi:10.1016/j.ccr.2013.11.002. PMC 3904731. PMID 24332040.
Arnold MA, Barr FG (2017). "Molecular diagnostics in the management of rhabdomyosarcoma". Expert Review of Molecular Diagnostics. 17 (2): 189–194. doi:10.1080/14737159.2017.1275965. PMC 5657295. PMID 28058850.
Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (September 2009). "Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005". Cancer. 115 (18): 4218–4226. doi:10.1002/cncr.24465. PMC 2953716. PMID 19536876.
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. (January 2019). "Rhabdomyosarcoma". Nature Reviews. Disease Primers. 5 (1): 1. doi:10.1038/s41572-018-0051-2. PMC 7456566. PMID 30617281.
Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, et al. (2021). "Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium". Journal of Clinical Oncology. 39 (26): 2859–2871. doi:10.1200/JCO.20.03060. PMC 8425837. PMID 34166060.
Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, et al. (2018). "MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma". Science Translational Medicine. 10 (448): eaan4470. doi:10.1126/scitranslmed.aan4470. PMC 8054766. PMID 29973406.
Agaram NP (2022). "Evolving classification of rhabdomyosarcoma". Histopathology. 80 (1): 98–108. doi:10.1111/his.14449. PMC 9425116. PMID 34958505. S2CID 245501811.
Parham DM, Barr FG (2013). "Classification of rhabdomyosarcoma and its molecular basis". Advances in Anatomic Pathology. 20 (6): 387–397. doi:10.1097/PAP.0b013e3182a92d0d. PMC 6637949. PMID 24113309.
Frankart AJ, Breneman JC, Pater LE (2021). "Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma". Cancers. 13 (14): 3567. doi:10.3390/cancers13143567. PMC 8305800. PMID 34298780.
Wang X, Feng J, Li Z, Zhang X, Chen J, Feng G (2020). "Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database". Pediatric Investigation. 4 (4): 242–249. doi:10.1002/ped4.12220. PMC 7768301. PMID 33376951.
Frankart AJ, Breneman JC, Pater LE (2021). "Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma". Cancers. 13 (14): 3567. doi:10.3390/cancers13143567. PMC 8305800. PMID 34298780.
Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, et al. (2014). "A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations". Nature Genetics. 46 (6): 595–600. doi:10.1038/ng.2969. PMC 4231202. PMID 24793135.
Rudzinski ER, Anderson JR, Hawkins DS, Skapek SX, Parham DM, Teot LA (2015). "The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group". Archives of Pathology & Laboratory Medicine. 139 (10): 1281–1287. doi:10.5858/arpa.2014-0475-OA. PMC 4651658. PMID 25989287.
Chen C, Dorado Garcia H, Scheer M, Henssen AG (2019). "Current and Future Treatment Strategies for Rhabdomyosarcoma". Frontiers in Oncology. 9: 1458. doi:10.3389/fonc.2019.01458. PMC 6933601. PMID 31921698.
Hiniker SM, Donaldson SS (2015-05-12). "Recent advances in understanding and managing rhabdomyosarcoma". F1000Prime Reports. 7: 59. doi:10.12703/P7-59. PMC 4447051. PMID 26097732.
Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H (July 2020). "Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma". Cancers. 12 (7): 1758. doi:10.3390/cancers12071758. PMC 7409313. PMID 32630642.

semanticscholar.org

api.semanticscholar.org

Rodeberg D, Paidas C (2006). "Childhood rhabdomyosarcoma". Seminars in Pediatric Surgery. Childhood Cancer. 15 (1): 57–62. doi:10.1053/j.sempedsurg.2005.11.009. PMID 16458847. S2CID 1220308.
Fan R, Parham DM, Wang LL (2022). "An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma". Archives of Pathology & Laboratory Medicine. 146 (8): 953–959. doi:10.5858/arpa.2021-0183-RA. PMID 35051261. S2CID 246078793.
Leiner J, Le Loarer F (2020). "The current landscape of rhabdomyosarcomas: an update". Virchows Archiv. 476 (1): 97–108. doi:10.1007/s00428-019-02676-9. PMID 31696361. S2CID 207911529.
Agaram NP (2022). "Evolving classification of rhabdomyosarcoma". Histopathology. 80 (1): 98–108. doi:10.1111/his.14449. PMC 9425116. PMID 34958505. S2CID 245501811.
Jawad N, McHugh K (2019). "The clinical and radiologic features of paediatric rhabdomyosarcoma". Pediatric Radiology. 49 (11): 1516–1523. doi:10.1007/s00247-019-04386-5. PMID 31620851. S2CID 204709484.
Breitfeld PP, Meyer WH (2005). "Rhabdomyosarcoma: new windows of opportunity". The Oncologist. 10 (7): 518–527. doi:10.1634/theoncologist.10-7-518. PMID 16079319. S2CID 24136175.
Darwish C, Shim T, Sparks AD, Chillakuru Y, Strum D, Benito DA, Monfared A (December 2020). "Pediatric head and neck rhabdomyosarcoma: An analysis of treatment and survival in the United States (1975-2016)". International Journal of Pediatric Otorhinolaryngology. 139: 110403. doi:10.1016/j.ijporl.2020.110403. PMID 33049553. S2CID 222351840.
van Erp AE, Versleijen-Jonkers YM, van der Graaf WT, Fleuren ED (July 2018). "Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma". Molecular Cancer Therapeutics. 17 (7): 1365–1380. doi:10.1158/1535-7163.MCT-17-1131. PMID 29967215. S2CID 49648448.